ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP ยท Real-Time Price ยท USD
10.52
-0.74 (-6.57%)
Nov 20, 2026, 4:00 PM EST - Market closed
ArriVent BioPharma Earnings Call Transcripts
Fiscal Year 2026
-
ARR-217 showed a 44.8% ORR and 93.1% DCR at 6 mg/kg in heavily pretreated metastatic CRC, with mostly low-grade toxicity and 2% Grade 3 diarrhea. Phase Ib monotherapy and combination studies continue; phase III initiation is targeted by end-2027.
-
The meeting confirmed a quorum and proceeded virtually, electing three directors for terms ending in 2029 and ratifying PricewaterhouseCoopers LLP as auditor for 2026. No questions were received from stockholders during the Q&A session.